$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 10 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 45.33 | 83,143 | 3,768,872 | 1,819,920 | 1.9 M to 1.8 M (-4.37 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 125,751 | |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 47.64 | 100 | 4,764 | 10,000 | 10.1 K to 10 K (-0.99 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 46.76 | 200 | 9,352 | 10,100 | 10.3 K to 10.1 K (-1.94 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 45.79 | 300 | 13,737 | 10,300 | 10.6 K to 10.3 K (-2.83 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 44.84 | 1,600 | 71,744 | 10,600 | 12.2 K to 10.6 K (-13.11 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 44.21 | 1,100 | 48,631 | 12,200 | 13.3 K to 12.2 K (-8.27 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 42.86 | 1,300 | 55,718 | 13,300 | 14.6 K to 13.3 K (-8.90 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 41.18 | 200 | 8,236 | 14,600 | 14.8 K to 14.6 K (-1.35 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 39.52 | 200 | 7,904 | 14,800 | 15 K to 14.8 K (-1.33 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 47.23 | 196 | 9,257 | 15,000 | 15.2 K to 15 K (-1.29 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 46.39 | 300 | 13,917 | 15,196 | 15.5 K to 15.2 K (-1.94 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 45.17 | 1,000 | 45,170 | 15,496 | 16.5 K to 15.5 K (-6.06 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 44.34 | 1,759 | 77,994 | 16,496 | 18.3 K to 16.5 K (-9.64 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 42.96 | 1,344 | 57,738 | 18,255 | 19.6 K to 18.3 K (-6.86 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 41.14 | 100 | 4,114 | 19,599 | 19.7 K to 19.6 K (-0.51 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.34 | 201 | 8,108 | 19,699 | 19.9 K to 19.7 K (-1.01 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 38.52 | 100 | 3,852 | 19,900 | 20 K to 19.9 K (-0.50 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 20,000 | 10 K to 20 K (+100.00 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 47.45 | 451 | 21,400 | 76,500 | 77 K to 76.5 K (-0.59 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 46.54 | 1,200 | 55,848 | 76,951 | 78.2 K to 77 K (-1.54 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 45.10 | 4,300 | 193,930 | 78,151 | 82.5 K to 78.2 K (-5.22 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 44.35 | 7,036 | 312,047 | 82,451 | 89.5 K to 82.5 K (-7.86 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 42.90 | 5,413 | 232,218 | 89,487 | 94.9 K to 89.5 K (-5.70 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 41.58 | 400 | 16,632 | 94,900 | 95.3 K to 94.9 K (-0.42 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 40.55 | 800 | 32,440 | 95,300 | 96.1 K to 95.3 K (-0.83 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 38.43 | 400 | 15,372 | 96,100 | 96.5 K to 96.1 K (-0.41 %) |
| Dec 09 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 45.00 | 23,400 | 1,053,000 | 114,231 | 137.6 K to 114.2 K (-17.00 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 8,500 | |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 37.44 | 1,100 | 41,184 | 27,890 | 29 K to 27.9 K (-3.79 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 36.10 | 1,000 | 36,100 | 28,990 | 30 K to 29 K (-3.33 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 34.87 | 1,900 | 66,253 | 29,990 | 31.9 K to 30 K (-5.96 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 31,890 | 27.9 K to 31.9 K (+14.34 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 2,500 | 12,700 | 6,250 | |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 1.80 | 2,969 | 5,344 | 11,094 | |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 2,031 | 1,869 | 0 | |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 37.41 | 700 | 26,187 | 52,656 | 53.4 K to 52.7 K (-1.31 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 36.16 | 600 | 21,696 | 53,356 | 54 K to 53.4 K (-1.11 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 34.89 | 1,200 | 41,868 | 53,956 | 55.2 K to 54 K (-2.18 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 2,500 | 12,700 | 55,156 | 52.7 K to 55.2 K (+4.75 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 37.27 | 1,300 | 48,451 | 52,656 | 54 K to 52.7 K (-2.41 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 36.24 | 1,100 | 39,864 | 53,956 | 55.1 K to 54 K (-2.00 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 34.97 | 2,600 | 90,922 | 55,056 | 57.7 K to 55.1 K (-4.51 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 1.80 | 2,969 | 5,344 | 57,656 | 54.7 K to 57.7 K (+5.43 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 2,031 | 1,869 | 54,687 | 52.7 K to 54.7 K (+3.86 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,082 | 1,959 | 36,000 | |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 34.51 | 300 | 10,353 | 22,500 | 22.8 K to 22.5 K (-1.32 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.42 | 700 | 23,394 | 22,800 | 23.5 K to 22.8 K (-2.98 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 34.54 | 907 | 31,328 | 19,940 | 20.8 K to 19.9 K (-4.35 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.54 | 3,175 | 106,490 | 20,847 | 24 K to 20.8 K (-13.22 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 4,082 | 1,959 | 24,022 | 19.9 K to 24 K (+20.47 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 7,500 | |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 34.72 | 675 | 23,436 | 0 | 675 to 0 (-100.00 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.24 | 3,325 | 110,523 | 675 | 4 K to 675 (-83.12 %) |
| Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 1,899 | 13,521 | 7,031 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 3,101 | 18,234 | 9,399 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.60 | 3,043 | 102,245 | 0 | 3 K to 0 (-100.00 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 32.42 | 1,957 | 63,446 | 3,043 | 5 K to 3 K (-39.14 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 1,899 | 13,521 | 5,000 | 3.1 K to 5 K (+61.24 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 3,101 | 18,234 | 3,101 | 0 to 3.1 K |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 5,000 | 26,400 | 16,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 1,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 14,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 12,000 | 420,000 | 27,890 | 39.9 K to 27.9 K (-30.08 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 5,000 | 26,400 | 39,890 | 34.9 K to 39.9 K (+14.33 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 34,890 | 29.9 K to 34.9 K (+16.73 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 33.56 | 2,400 | 80,544 | 29,890 | 32.3 K to 29.9 K (-7.43 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.46 | 1,600 | 51,936 | 32,290 | 33.9 K to 32.3 K (-4.72 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,504 | 7,640 | 33,496 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 2,414 | 4,345 | 0 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.70 | 400 | 13,480 | 23,500 | 23.9 K to 23.5 K (-1.67 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.64 | 600 | 19,584 | 23,900 | 24.5 K to 23.9 K (-2.45 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.59 | 2,317 | 77,828 | 19,940 | 22.3 K to 19.9 K (-10.41 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.43 | 1,601 | 51,920 | 22,257 | 23.9 K to 22.3 K (-6.71 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 5.08 | 1,504 | 7,640 | 23,858 | 22.4 K to 23.9 K (+6.73 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 2,414 | 4,345 | 22,354 | 19.9 K to 22.4 K (+12.11 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 135,751 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 33.58 | 3,138 | 105,374 | 10,000 | 13.1 K to 10 K (-23.88 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.39 | 1,862 | 60,310 | 13,138 | 15 K to 13.1 K (-12.41 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 33.60 | 3,050 | 102,480 | 15,000 | 18.1 K to 15 K (-16.90 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.44 | 1,950 | 63,258 | 18,050 | 20 K to 18.1 K (-9.75 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 20,000 | 10 K to 20 K (+100.00 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 5,000 | 25,400 | 8,750 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 313 | 288 | 2,031 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 4,687 | 4,312 | 0 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 33.60 | 2,964 | 99,590 | 52,656 | 55.6 K to 52.7 K (-5.33 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.45 | 2,036 | 66,068 | 55,620 | 57.7 K to 55.6 K (-3.53 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 5,000 | 25,400 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 33.62 | 2,935 | 98,675 | 52,656 | 55.6 K to 52.7 K (-5.28 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.48 | 2,065 | 67,071 | 55,591 | 57.7 K to 55.6 K (-3.58 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 313 | 288 | 57,656 | 57.3 K to 57.7 K (+0.55 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 4,687 | 4,312 | 57,343 | 52.7 K to 57.3 K (+8.90 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 33.57 | 9,399 | 315,524 | 96,500 | 105.9 K to 96.5 K (-8.88 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.57 | 10,601 | 345,275 | 105,899 | 116.5 K to 105.9 K (-9.10 %) |
| Nov 04 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 40.00 | 23,400 | 936,000 | 137,631 | 161 K to 137.6 K (-14.53 %) |
| Oct 28 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 35.00 | 17,872 | 625,520 | 161,031 | 178.9 K to 161 K (-9.99 %) |
| Oct 28 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 35.00 | 5,528 | 193,480 | 178,903 | 184.4 K to 178.9 K (-3.00 %) |
| Oct 27 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 145,751 | |
| Oct 27 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 10,000 | 0 to 10 K |
| Oct 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.12 | 1,000 | 29,120 | 24,500 | 25.5 K to 24.5 K (-3.92 %) |
| Oct 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.10 | 3,918 | 114,014 | 19,940 | 23.9 K to 19.9 K (-16.42 %) |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 11,500 | |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.02 | 4,000 | 116,080 | 0 | 4 K to 0 (-100.00 %) |
| Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 4,082 | 7,348 | 2,414 | |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.41 | 200 | 6,082 | 25,500 | 25.7 K to 25.5 K (-0.78 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.27 | 800 | 23,416 | 25,700 | 26.5 K to 25.7 K (-3.02 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.28 | 1,193 | 36,124 | 23,858 | 25.1 K to 23.9 K (-4.76 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.17 | 2,889 | 84,272 | 25,051 | 27.9 K to 25.1 K (-10.34 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 4,082 | 7,348 | 27,940 | 23.9 K to 27.9 K (+17.11 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 10,000 | 38,800 | 155,751 | |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.25 | 10,000 | 292,500 | 0 | 10 K to 0 (-100.00 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 10,000 | 38,800 | 10,000 | 0 to 10 K |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 30.20 | 10,000 | 302,000 | 116,500 | 126.5 K to 116.5 K (-7.91 %) |
| Oct 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.22 | 10,000 | 292,200 | 126,500 | 136.5 K to 126.5 K (-7.33 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 18,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 3,500 | 18,480 | 21,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 1,500 | 8,820 | 6,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.36 | 608 | 18,459 | 29,890 | 30.5 K to 29.9 K (-1.99 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.57 | 3,392 | 100,301 | 30,498 | 33.9 K to 30.5 K (-10.01 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 29,890 | 36.9 K to 29.9 K (-18.98 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 3,500 | 18,480 | 36,890 | 33.4 K to 36.9 K (+10.48 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 1,500 | 8,820 | 33,390 | 31.9 K to 33.4 K (+4.70 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 5,000 | 25,400 | 13,750 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.92 | 3,125 | 2,875 | 4,687 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 1,875 | 750 | 0 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.28 | 900 | 27,252 | 52,656 | 53.6 K to 52.7 K (-1.68 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.53 | 4,100 | 121,073 | 53,556 | 57.7 K to 53.6 K (-7.11 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 5,000 | 25,400 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.27 | 800 | 24,216 | 52,656 | 53.5 K to 52.7 K (-1.50 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.53 | 4,200 | 124,026 | 53,456 | 57.7 K to 53.5 K (-7.28 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.92 | 3,125 | 2,875 | 57,656 | 54.5 K to 57.7 K (+5.73 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 1,875 | 750 | 54,531 | 52.7 K to 54.5 K (+3.56 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 3,570 | 25,418 | 8,930 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,430 | 18,110 | 13,707 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.01 | 7,000 | 210,070 | 0 | 7 K to 0 (-100.00 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 3,570 | 25,418 | 7,000 | 3.4 K to 7 K (+104.08 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,430 | 18,110 | 3,430 | 0 to 3.4 K |
| Sep 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 25.50 | 1,000 | 25,500 | 26,500 | 27.5 K to 26.5 K (-3.64 %) |
| Sep 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 25.47 | 4,000 | 101,880 | 23,858 | 27.9 K to 23.9 K (-14.36 %) |
| Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 15,500 | |
| Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 25.43 | 2,000 | 50,860 | 0 | 2 K to 0 (-100.00 %) |
| Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 6,700 | 25,996 | 165,751 | |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,300 | 12,804 | 172,451 | |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 24.75 | 370 | 9,158 | 0 | 370 to 0 (-100.00 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 24.24 | 6,330 | 153,439 | 370 | 6.7 K to 370 (-94.48 %) |